SCHEMBL4958812

SCHEMBL4958812

CSc1ccc(-c2ncccc2C(=O)c2cccc(F)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.40
BCR P11274 2/20 0.40
CHRNA7 P36544 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
RORB Q92753 1/20 0.39
USP2 O75604 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4957447 0.82 PTGS2 (0.57) PTGS1PTGS2
SCHEMBL4963355 0.81 RAB9A (0.42) NPC1RAB9ASMN1; SMN2
SCHEMBL4958940 0.77 RAB9A (0.45) RORBCES2CES1NPC1RAB9A
SCHEMBL7810937 0.76 CES2 (0.52) CYP1A2CYP3A4CES2CES1KMT2A
SCHEMBL4958819 0.73 KMT2A (0.41) ABL1BCRUSP2CYP1A2CYP3A4
SCHEMBL4960341 0.72 USP2 (0.52) USP2CYP1A2CYP3A4CES2CES1
SCHEMBL11471987 0.70 KMT2A (0.55) RORBCYP3A4NPC1RAB9AKMT2A
SCHEMBL8586217 0.68 KMT2A (0.66) USP2CYP1A2CES2CES1NPC1
SCHEMBL14484865 0.68 ALDH1A1 (0.50) ABL1BCRLMNASMN1; SMN2
SCHEMBL5935113 0.67 GAA (0.47) NPC1RAB9AKMT2ALMNATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542972-A4 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-01-23 EP disclosed
US-20070238735-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITRODMED, INC. (US) 2007-10-11 US disclosed
US-7244753-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2007-07-17 US disclosed
EP-1542972-A2 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-22 EP disclosed
US-20040072883-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-04-15 US disclosed
WO-2004010945-A2 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072883-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 ABL1 1724/4885BCR 4051/4885CHRNA7 4626/4885
US-20070238735-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGS1 ABL1 1652/4885BCR 3981/4885CHRNA7 4504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.